AbbVie (ABBV) Other financing activities (2012 - 2026)

AbbVie has disclosed Other financing activities across 15 years of filings, most recently posting $2.0 million for Q1 2026.

• In Q1 2026, Other financing activities fell 97.01% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 88.0% YoY), while the FY2025 annual figure was $68.0 million, up 19.3% from the prior year.
• Other financing activities retreated to $2.0 million in Q1 2026, from $45.0 million in the prior quarter.
• Over the last five years, Other financing activities for ABBV reached as high as $99.0 million in Q1 2024 and fell as low as -$75.0 million in Q2 2024.
• The 5-year median for Other financing activities is $10.0 million (2022), against an average of $12.8 million.
• Annual changes were most pronounced in 2022 — Other financing activities slumped 650.0% — and 2025, when it soared 4400.0%.
• A 5-year view of Other financing activities shows it stood at -$11.0 million in 2022, then surged by 536.36% to $48.0 million in 2023, then sank by 97.92% to $1.0 million in 2024, then soared by 4400.0% to $45.0 million in 2025, then slumped by 95.56% to $2.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $2.0 million, $45.0 million, and -$9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.